Jesper Söderqvist appointed new CEO of Boule Diagnostics

The Board of Directors of Boule Diagnostics AB has appointed Jesper Söderqvist as the new CEO and Group President with effect no later than May 11, 2020. Jesper has 15 years of experience of senior management positions in med-tech companies and a broad experience of sales, marketing, development and production. Jesper arrives most recently from the First North listed company Arcoma AB. Before that he was Vice President Portfolio Management of Elekta overseeing neuro products. Jesper was from 2004 to 2011 the CEO of Sectra AB’s subsidiary Sectra Mamea AB, responsible for developing the organization from a start-up to a global actor with sales in 24 countries and participated in the successful sale to Philips in 2011, where he remained in the same role until 2014. Jesper holds a Master of Science in engineering and a PhD in physics, both from the Royal Institute of Technology in Stockholm.

“We are very pleased to be able to get Jesper to join Boule, his competence profile and personality fit very well with how we see Boule developing going forward”, says Peter Ehrenheim, Chairman of the Board.

”I’m very happy to become a part of Boule and to lead a company with an impressive history and product portfolio as well as a large global distribution network. Near-patient blood diagnostics are an increasingly important healthcare tool and Boule has a unique position in this growing market. I’m looking forward to work with Boule’s competent employees, Board of Directors, distributors and customers in order to take the next step in the company’s development”, comments Jesper Söderqvist on the appointment.   

For further information, please contact:
Peter Ehrenheim, Chairman of the Board, Boule Diagnostics AB, phone. + 46 706-67 57 11

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com

This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 18:00 CET on November 11, 2019.

Release